Bioavailability and Analgesic Effect of Sustained Release Cetobemidone Capsules in Cancer Patients with Chronic Pain of Malignant Origin

References

• Petersen P V. Studies on a new spasomlytic compound 1.1-diphenyl-3-dimethylaminobutene-1 (A29). related to methadone and on the combined use of this compound and a potent analgesic. Ketobemidone (A21). Acta Pharmacol Toxicol 1951; 7: 51–64
   PubMedGoogle Scholar
• Säwe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinetic 1986; 11: 87–106
   PubMed Web of Science ®Google Scholar
• Andersson P, Arnér S, Bondesson U, Boréus L O, Hartvig P. Pharmacokinetics of ketobemidone. Adv Pain Res Ther 1986; 8: 171–8
   Google Scholar
• Hanks G W. Controlled-release morphine (MST Contin) in advanced cancer. The European experience. Cancer 1989; 63: 2378–82
   PubMed Web of Science ®Google Scholar
• Andersson P, Arnér S, Bondesson U, Boréus L O, Hartvig P. Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration. Eur J Clin Pharmacol 1981; 19: 217–23
   PubMedGoogle Scholar
• Andersson P, Arnér S, Bondesson U, Boréus L O, Hartvig P. Single-dose kinetics and bioavailability of ketobemidone. Acta Anaesthresiol Scand 1982; 59–62, (Suppl. 74)
   Google Scholar
• Bondesson U, Arnér S, Andersson P, Hartvig P. Clinical phamacokinetics and oral bioavailability of ketobemidone. Eur J Clin Pharmacol 1980; 17: 45–50
   PubMedGoogle Scholar
• Bondesson U, Tamsen A, Dahlström B, Hartvig P. Multiple dose kinetics of ketobemidone in surgical patients. Acta Anaesthesiol Scand 1982; 63–5, (Suppl. 74)
   PubMedGoogle Scholar
• Kjaer M, Nielsen H. Analgesic erect and bioavailability of oral Ketogan given as tablets or mixture to patients with chronic pain of malignant origin. Acta Oncol 1988; 27: 583–9
   PubMed Web of Science ®Google Scholar
• WHO Handbook for reporting results of cancer treatment. World Health Organization, Geneva 1979, WHO Offset Publication No. 48
   Google Scholar
• Kjaer M, Henriksen H, Knudsen J. A comparative study of intramuscular buprenmorphine and morphine in the treatment of chronic pain of malignant origin. Br J Chi Pharmacol 1982; 13: 487–92
   PubMedGoogle Scholar
• Kjaer M, Nielsen H. The analgesic erect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase 1–2 study. Br J Clin Pharmacol 1983; 16: 477–85
   PubMed Web of Science ®Google Scholar
• Nielsen H. Use of enzymatic solubilization of tissues and direct injection on pre-columns of large volumes for analysing biological samples by high performance liquid chromatography. J Chromatogr 1986; 281: 63–74
   Google Scholar
• Khojastek A, Evans W, Reynolds R D, Thomas G, Savarese J J. Controlled-release oral morphine sulfate in the treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 1987; 5: 956–61
   PubMedGoogle Scholar
• Poulain P, Hoskin P J, Hanks G W, et al. Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesthesiol 1988; 61: 569–74
   PubMed Web of Science ®Google Scholar
• Thirwell M P, Sloan P A, Maroun J A, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; 63: 2275–83
   PubMed Web of Science ®Google Scholar
• Walsh T D. A controlled study of MST continus tablets for chronic pain in advanced cancer. Advances in morphine therapy, E Wilkes, 1984; 99–102, The 1983 International Symposium on Pain Control. Royal Society of Medicine International Congress and Symposium Series No. 64. Royal Soc. of Med
   Google Scholar
• Heriksen H, Knudsen J (1984) MST continus tablets in pain of advanced cancer: a controlled study. Advances in morphine therapy. The 1983 International Symposium on Pain Control. 1983, E Wilkes. Royal Society of Medicine, 123–6, Royal Society of Medicine International Congress and Symposium Series No. 64
   Google Scholar
• Hanks G W, Twycross R G, Bliss J M. Controlled release morphine tablets: A double-blind trial in patients with advanced cancer. Anaesthesia 1987; 42: 840–4
   PubMed Web of Science ®Google Scholar
• Arkinstall W W, Goughnour B R, White J A, Stewart J H. Control of severe pain with sustained-release morphine tablets versus oral morphine solution. Can Med Assoc J 1989; 140: 655–61
   Google Scholar
• Bates T D, Kearney M K. Long-term control of pain in terminal cancer with MST continus tablets, D Doyle. Royal Soc. of Med. Services Ltd., London 1987; 5–12, Royal Soc. Med. Service Int. Congress and Symp. Series No. 123
   Google Scholar
• Warfield C A. Evaluation of dosing guidelines for the use of oral controlled-release morphine (MS continus tablets). Cancer 1989; 63: 2360–4
   PubMedGoogle Scholar